Sutent Adjunctive Treatment of Differentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2015

Study Completion Date

December 31, 2015

Conditions
Papillary Thyroid CancerFollicular Thyroid CancerDifferentiated Thyroid Cancer
Interventions
DRUG

SU011248, Sutent

Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.

Trial Locations (1)

20010

MedStar Washington Hospital Center, Washington D.C.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Medstar Health Research Institute

OTHER